YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Healthcare stocks were mixed late Tuesday afternoon, with the NYSE Healthcare Index up 0.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Healthcare stocks were mixed Tuesday afternoon, with the NYSE Healthcare Index up 0.1% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* Jupiter Neurosciences (JUNS [https://seekingalpha.com/symbol/JUNS]) on Friday said it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. * Shares…
By Mike Sheikh Parkinson's Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn't recognizing the story yet wit…
(RTTNews) - Jupiter Neurosciences, Inc. (JUNS), a clinical-stage biopharmaceutical company focused on therapies for neurological and neurodegenerative disorders, has approved a 1-for-75 reverse stock split of its common stock. The move, ba…
Jupiter Neurosciences, Inc. Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "C…
Jupiter’s common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage b…
Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, President and Chief Operations Offi…
Emerging Growth MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference id…
Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-st…
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today anno…
medical research 12 ©sharevault.com The proposed agreement would grant Jupiter Neurosciences exclusive U.S. rights to PharmAla’s lead psychedelic drug candidate while allowing PharmAla to retain international commercialization rights. Key…
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neur…
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are no…
Virtual Investor Conferences NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, h…
Virtual Investor Conferences Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary inve…
IPO Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Christer Rosen, Chairman and Chief Executive Officer, and Alison Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). The in-pe…
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc (“JUNS” or the “Company”) (NASDAQ: JUNS), a clinical stage biopha…
Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today ann…
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT TRIB [https://www.chartmill.com/stock/quote/TR…
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical co…
JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced Thursday it has regained compliance with Nasdaq’s minimum share price requirement, according to a statement based on a company press release. The stock, currently trading at…
* Jupiter Neurosciences has regained compliance with Nasdaq's $1 minimum bid price rule. * Nasdaq confirmed that JUNS stock maintained a $1.00+ average closing price from June 18 to July 8, 2025. * Nasdaq now considers the compliance matte…
Jupiter Neurosciences, Inc. Nasdaq compliance follows positive upward trend in Company’s Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-st…
Nasdaq compliance follows positive upward trend in Company’s Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company d…
Jupiter Neurosciences , Inc. (NASDAQ:JUNS) announced that its board’s Compensation Committee approved a bonus package for key executives, according to a statement released Wednesday based on a recent SEC filing. On July 2, the committee ap…
PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the…
Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today annou…
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a…